Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03877692 · ClinicalTrials.gov registry record · Phase 4
Acute Control of Chronic Hypertension
A Phase 4 study, sponsored by Albany Medical College.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT03877692 is a Phase 4 study that was terminated before completion, run by Albany Medical College. The registered enrollment target is 10 participants.
The verdict
NCT03877692, a Phase 4 study, was terminated before completion, sponsored by Albany Medical College.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's history of preexisting hypertension, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dosing.
Interventions
- DRUG Experimental dosing of labetalol
- OTHER Standard dosing of labetalol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-02-18 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03877692
The ClinicalTrials.gov registry entry for NCT03877692 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albany Medical College, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Experimental dosing of labetalol is the first listed.
NCT03877692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03877692 about?
NCT03877692 is a clinical study titled "Acute Control of Chronic Hypertension". The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's history of preexisting hypertension, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dos...
What is the current status of trial NCT03877692?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2019-02-18. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT03877692?
The interventions under investigation include: Experimental dosing of labetalol (DRUG), Standard dosing of labetalol (OTHER).
Who is sponsoring clinical trial NCT03877692?
This trial is sponsored by Albany Medical College, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.